Kisqali (ribociclib) treats hormone receptor-positive (HR+), HER2-negative breast cancer. Doctors prescribe it for early and advanced stages, combining it with an aromatase inhibitor or fulvestrant (FDA, Mayo Clinic, Drugs.com). Clinical studies confirm its effectiveness in delaying disease progression (PubMed, WebMD) and improving patients’ outcomes (Healthline).

Key Benefits & Uses

• Doctors use Kisqali to improve progression-free survival in HR+/HER2- breast cancer (WHO, FDA).

• It reduces recurrence risk in early-stage patients (Mayo Clinic, Drugs.com).

• Patients benefit from oral administration, avoiding intravenous therapy (WebMD, Healthline).

How to Take Kisqali

Take Kisqali orally once daily for 21 consecutive days, followed by 7 days off. Swallow tablets whole with or without food (FDA, Mayo Clinic). If you miss a dose, take the next dose at the usual time and avoid doubling (Drugs.com, WebMD). Doctors monitor patients with blood tests and ECGs during treatment (PubMed).

Safety Information

Kisqali can cause serious side effects, including:

• Lung inflammation

• Severe skin reactions

• Heart rhythm problems (QT prolongation)

• Liver issues

• Low white blood cell counts (FDA, Mayo Clinic, Healthline)

Patients should report symptoms like jaundice, chest pain, or severe rash immediately (WebMD, WHO).

Common Side Effects

Patients may experience fatigue, nausea, headache, diarrhea, or hair thinning (Drugs.com, Healthline). Most side effects are manageable when patients follow their healthcare provider’s advice (PubMed, WebMD).

Why Choose Kisqali

Doctors recommend Kisqali for its proven results in early and advanced HR+/HER2- breast cancer (FDA, Mayo Clinic, Healthline). Its oral form provides convenience, and clinical trials demonstrate its ability to improve progression-free survival (PubMed, WHO). FDA approval for early-stage breast cancer highlights its growing clinical significance (Drugs.com, WebMD).